GSK plc has completed its previously announced acquisition of IDRx Inc., a Boston-based, clinical-stage biopharmaceutical ...

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, ...

GSK (GSK) plc announced that it has completed the acquisition of IDRx, Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated ...

GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.

GSK on Monday also said it has start the GBP2 billion buyback programme that it announced earlier this month, starting with an initial GBP700 million tranche.

and completed a $120 million Series B last August to fund clinical development of lead cancer drug candidate IDRX-42, which hiked its valuation to around $430 million. The company had also been ...

The financing involves the payment of an advance of $1 billion. The deal includes the acquisition of IDRX-42, a highly selective aTKI kit being developed as a first- and second-line therapy for the ...

IDRX-42, in development for this rare type of cancer. IDRx received $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment.